The risk of malignancy associated with psoriasis

David Margolis, Warren Bilker, Sean Hennessy, Carmela Vittorio, Jill Santanna, Brian L. Strom

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Objective: To measure the incidence of cancer in patients with psoriasis, stratified by the severity of their disease. Design: A cohort study. Setting: Administrative claims records obtained from Medicaid programs in 3 US states. Participants: All individuals in the claims database who qualified for 1 of the 5 following groups: severe psoriasis as defined by treatment with systemic medication, less severe psoriasis, severe eczema, history of organ transplantation, and hypertension. Main Outcome Measure: A diagnosis of cancer. Results: Individuals with severe psoriasis were more likely to develop a malignancy than those with hypertension (risk ratio, 1.78; 95% confidence interval [CI], 1.32-2.40). The risk of malignancy in the severe psoriasis group approaches that in patients with organ transplants (risk ratio, 2.12; 95% CI, 1.80-2.50). Most of these cancers were nonmelanoma skin cancers and lymphoproliferative malignancies. Those with less severe psoriasis were only slightly more likely to develop a new malignancy than those with hypertension (risk ratio, 1.13; 95% CI, 1.03-1.25). Conclusions: Patients with psoriasis are at an increased risk of developing a malignancy compared with patients with hypertension. The increased risk is greatest for those with severe disease (ie, patients with psoriasis treated with systemic agents) and minimal (if an increased risk at all) for those with less severe disease compared with those in the hypertension group. The increased risk is mainly for lymphoproliferative cancers and nonmelanoma skin cancers.

Original languageEnglish (US)
Pages (from-to)778-783
Number of pages6
JournalArchives of dermatology
Volume137
Issue number6
StatePublished - Jul 7 2001

Fingerprint

Psoriasis
Hypertension
Neoplasms
Skin Neoplasms
Odds Ratio
Confidence Intervals
Eczema
Medicaid
Organ Transplantation
Cohort Studies
Outcome Assessment (Health Care)
Databases
Transplants
Incidence

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Margolis, D., Bilker, W., Hennessy, S., Vittorio, C., Santanna, J., & Strom, B. L. (2001). The risk of malignancy associated with psoriasis. Archives of dermatology, 137(6), 778-783.
Margolis, David ; Bilker, Warren ; Hennessy, Sean ; Vittorio, Carmela ; Santanna, Jill ; Strom, Brian L. / The risk of malignancy associated with psoriasis. In: Archives of dermatology. 2001 ; Vol. 137, No. 6. pp. 778-783.
@article{e793766ecf8f45eb8e2e306e1a5ea3d1,
title = "The risk of malignancy associated with psoriasis",
abstract = "Objective: To measure the incidence of cancer in patients with psoriasis, stratified by the severity of their disease. Design: A cohort study. Setting: Administrative claims records obtained from Medicaid programs in 3 US states. Participants: All individuals in the claims database who qualified for 1 of the 5 following groups: severe psoriasis as defined by treatment with systemic medication, less severe psoriasis, severe eczema, history of organ transplantation, and hypertension. Main Outcome Measure: A diagnosis of cancer. Results: Individuals with severe psoriasis were more likely to develop a malignancy than those with hypertension (risk ratio, 1.78; 95{\%} confidence interval [CI], 1.32-2.40). The risk of malignancy in the severe psoriasis group approaches that in patients with organ transplants (risk ratio, 2.12; 95{\%} CI, 1.80-2.50). Most of these cancers were nonmelanoma skin cancers and lymphoproliferative malignancies. Those with less severe psoriasis were only slightly more likely to develop a new malignancy than those with hypertension (risk ratio, 1.13; 95{\%} CI, 1.03-1.25). Conclusions: Patients with psoriasis are at an increased risk of developing a malignancy compared with patients with hypertension. The increased risk is greatest for those with severe disease (ie, patients with psoriasis treated with systemic agents) and minimal (if an increased risk at all) for those with less severe disease compared with those in the hypertension group. The increased risk is mainly for lymphoproliferative cancers and nonmelanoma skin cancers.",
author = "David Margolis and Warren Bilker and Sean Hennessy and Carmela Vittorio and Jill Santanna and Strom, {Brian L.}",
year = "2001",
month = "7",
day = "7",
language = "English (US)",
volume = "137",
pages = "778--783",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "6",

}

Margolis, D, Bilker, W, Hennessy, S, Vittorio, C, Santanna, J & Strom, BL 2001, 'The risk of malignancy associated with psoriasis', Archives of dermatology, vol. 137, no. 6, pp. 778-783.

The risk of malignancy associated with psoriasis. / Margolis, David; Bilker, Warren; Hennessy, Sean; Vittorio, Carmela; Santanna, Jill; Strom, Brian L.

In: Archives of dermatology, Vol. 137, No. 6, 07.07.2001, p. 778-783.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The risk of malignancy associated with psoriasis

AU - Margolis, David

AU - Bilker, Warren

AU - Hennessy, Sean

AU - Vittorio, Carmela

AU - Santanna, Jill

AU - Strom, Brian L.

PY - 2001/7/7

Y1 - 2001/7/7

N2 - Objective: To measure the incidence of cancer in patients with psoriasis, stratified by the severity of their disease. Design: A cohort study. Setting: Administrative claims records obtained from Medicaid programs in 3 US states. Participants: All individuals in the claims database who qualified for 1 of the 5 following groups: severe psoriasis as defined by treatment with systemic medication, less severe psoriasis, severe eczema, history of organ transplantation, and hypertension. Main Outcome Measure: A diagnosis of cancer. Results: Individuals with severe psoriasis were more likely to develop a malignancy than those with hypertension (risk ratio, 1.78; 95% confidence interval [CI], 1.32-2.40). The risk of malignancy in the severe psoriasis group approaches that in patients with organ transplants (risk ratio, 2.12; 95% CI, 1.80-2.50). Most of these cancers were nonmelanoma skin cancers and lymphoproliferative malignancies. Those with less severe psoriasis were only slightly more likely to develop a new malignancy than those with hypertension (risk ratio, 1.13; 95% CI, 1.03-1.25). Conclusions: Patients with psoriasis are at an increased risk of developing a malignancy compared with patients with hypertension. The increased risk is greatest for those with severe disease (ie, patients with psoriasis treated with systemic agents) and minimal (if an increased risk at all) for those with less severe disease compared with those in the hypertension group. The increased risk is mainly for lymphoproliferative cancers and nonmelanoma skin cancers.

AB - Objective: To measure the incidence of cancer in patients with psoriasis, stratified by the severity of their disease. Design: A cohort study. Setting: Administrative claims records obtained from Medicaid programs in 3 US states. Participants: All individuals in the claims database who qualified for 1 of the 5 following groups: severe psoriasis as defined by treatment with systemic medication, less severe psoriasis, severe eczema, history of organ transplantation, and hypertension. Main Outcome Measure: A diagnosis of cancer. Results: Individuals with severe psoriasis were more likely to develop a malignancy than those with hypertension (risk ratio, 1.78; 95% confidence interval [CI], 1.32-2.40). The risk of malignancy in the severe psoriasis group approaches that in patients with organ transplants (risk ratio, 2.12; 95% CI, 1.80-2.50). Most of these cancers were nonmelanoma skin cancers and lymphoproliferative malignancies. Those with less severe psoriasis were only slightly more likely to develop a new malignancy than those with hypertension (risk ratio, 1.13; 95% CI, 1.03-1.25). Conclusions: Patients with psoriasis are at an increased risk of developing a malignancy compared with patients with hypertension. The increased risk is greatest for those with severe disease (ie, patients with psoriasis treated with systemic agents) and minimal (if an increased risk at all) for those with less severe disease compared with those in the hypertension group. The increased risk is mainly for lymphoproliferative cancers and nonmelanoma skin cancers.

UR - http://www.scopus.com/inward/record.url?scp=0034973031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034973031&partnerID=8YFLogxK

M3 - Article

C2 - 11405770

AN - SCOPUS:0034973031

VL - 137

SP - 778

EP - 783

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 6

ER -

Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Archives of dermatology. 2001 Jul 7;137(6):778-783.